Loading...
Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
Krebs, Matthew G Tarruella, M. M. Forster, M. Peguero, J. A. Clay, T. Felip, E. Iams, W. Roxburgh, P. de Speville, B. D. Bajaj, P.
Krebs, Matthew G
Tarruella, M. M.
Forster, M.
Peguero, J. A.
Clay, T.
Felip, E.
Iams, W.
Roxburgh, P.
de Speville, B. D.
Bajaj, P.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Krebs MG, Majem Tarruella M, Forster M, Peguero JA, Clay T, Felip E, et al. 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S33.